Advertisement

Search Results

Advertisement



Your search for Lee S. Schwartzberg, MD, FACP matches 15 pages

Showing 1 - 15


breast cancer
bladder cancer
colorectal cancer
lung cancer
multiple myeloma
immunotherapy

Conference Highlights From the ASCO20 Virtual Scientific Program

The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...

issues in oncology
immunotherapy

Lee S. Schwartzberg, MD, FACP: 2019 Update on the ACCC Immuno-Oncology Institute: Using Immunotherapy in the Community Setting

Lee S. Schwartzberg, MD, of the West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.

2019 ASCO Election Candidates

The ASCO Nominating Committee has selected 15 distinguished ASCO members as candidates for open leadership positions within the Society, including: The office of President-Elect Three seats on the Society’s Board of Directors Three seats on the Nominating Committee Biographical information and...

issues in oncology

Novel Physician-Driven Practice Model Offers Alternative to Community Oncologists

Three leading oncology practices have united with partners in technology and finance to launch OneOncology, a physician-driven company that aims to unite more than 225 community oncology providers from 60-plus locations. Altogether, OneOncology will treat nearly 158,000 cancer patients a year. The...

A Humble Beginning Built on Commitment: The Life and Times of Lee S. Schwartzberg, MD, FACP

  In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed medical oncologist Lee S. Schwartzberg, MD, FACP, Executive Director at the West Cancer Center, Memphis. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer,...

issues in oncology
immunotherapy

New ACCC Report Focuses on Immuno-Oncology, Cancer Care Delivery

As innovations in immunotherapies multiply, cancer programs and practices must overcome care coordination and communication challenges across the nation’s health-care system to integrate these advances into effective patient care. A new report from the Association of Community Cancer Centers...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

breast cancer

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.

Collaborative Exchange: The Expanded Access Program and Uridine Triacetate

The panel discussed the various aspects of obtaining a drug such as uridine triacetate through the expanded access program. Ms. Vogel: The expanded access program allows companies to provide patients access to their medicines while the drugs are still in preapproval process, but it is strictly...

Collaborative Exchange: Timing of Uridine Triacetate

The challenge of deciding when to administer uridine triacetate was explored by the panel. Dr. Schwartzberg: I assume uridine triacetate would work more effectively if given very early; otherwise we would see the same kind of downstream toxicity we see with methotrexate. Dr. Campen: Exactly, but...

Collaborative Exchange: Leucovorin and Glucarpidase

The panel discussed the rationale behind the continued use of leucovorin in conjunction with glucarpidase. Dr. Campen: We continue with leucovorin to provide a full basis for recovery of the cells. One important thing to know is that leucovorin should be given separately from glucarpidase because...

Collaborative Exchange: Indications and Dosing

Indications and Dosing of Methotrexate and 5-FU Dr. Campen: The interesting thing about methotrexate is that it has been used for such a long time. You would think there would be a specific dose that would be considered “high dose,” but high dose is actually quite variable. [Dosage] depends on the...

Meet the Panel

Based on a roundtable discussion conducted at the first annual JADPRO Live 2014 educational symposium in St. Petersburg, Florida, this supplement centers on strategies for preventing and treating severe side effects associated with methotrexate and fluorouracil (5-FU) from the unique perspectives...

supportive care

NEPA for Chemotherapy-Induced Nausea and Vomiting: Key Endpoints and Additional Analyses Show Strong Efficacy

For the prevention of chemotherapy-induced nausea and vomiting, NEPA, a novel combination of a neurokinin-1 (NK1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), has been studied in three pivotal trials that were recently published in the Annals of Oncology.1-3 Further...

ACCC Launches Immuno-Oncology Program for Community‐Based Cancer Care Providers

The Association of Community Cancer Centers (ACCC) has launched the Institute for Clinical Immuno-Oncology (ICLIO), a first-of-its-kind initiative aimed to facilitate the rapid adoption of immuno-oncology in the community cancer setting. To help with the rapid uptake of immuno-oncology at the...

Advertisement

Advertisement



Advertisement